JULY 19, 2016 BY FINK DENSFORD Orthobiologics maker Bioventus today released terms for its $150 million initial public offering, looking to float 8.8 million shares at between $16 and $18 per share, with plans to list on the NASDAQ Global Market under the ticker “BIOV”. At the midpoint of its proposed range, the company would command […]